ClinicalTrials.gg
CompletedNCT05882032Updated May 27, 2026Results posted

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

A Phase 1 interventional study of LY3502970 in Healthy and Hepatic Insufficiency, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hepatic Insufficiency by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Hepatic Insufficiency · Eli Lilly and Company.

Enrollment
10th of 12
29 · median 34
Started
2023
with 1 other
Phase 1
12 of 12
2 open now
Registered
7th of 12
by date

Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, this one is the 10th largest by enrollment, is one of 2 that started in 2023, is one of 12 in phase 1, and was the 7th registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

2 of the 12 studies in Hepatic Insufficiency by Eli Lilly and Company are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hepatic Insufficiency by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of LY3502970 will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.

03

Conditions studied

  • Healthy
  • Hepatic Insufficiency

Browse trials for

Keywords

  • LY3502970
  • Pharmacokinetics Hepatic Impairment
  • GLP-1 Receptor Non-peptide agonist (GLP-1 NPA)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women with body weight of at least 45 kilograms and a of 18.5 to 40.0 kilograms per meter squared (kg/m²).
  • Both healthy individuals and individuals with hepatic impairment classified as Score A, B, C that is mild, moderate, or severe impairment, respectively, liver disease can participate who are considered acceptable for participation in this study by the investigator.
  • Participants must have a diagnosis of chronic hepatic impairment for more than 6 months per physician diagnosis and standard of care practice, with no changes within 15 days prior to study intervention administration.
  • Participants may have mild stable baseline medical conditions for which neither the condition nor treatments received would negatively impact the health of the participant or study conduct.
  • Have acceptable BP and pulse rate, as determined by the investigator at screening.
  • No significant history of spontaneous or ethanol induced hypoglycemia.
  • Participants with Mild to Severe Hepatic Impairment who have a level of at least 8.5 grams/deciliter.
  • Participants with both T2DM and Hepatic Impairment have T2DM controlled with diet or exercise alone or on stable doses of anti-diabetic medications metformin or sulfonylureas, for at least 8 weeks prior to screening.
  • Participants with both T2DM and Hepatic Impairment have a greater than or equal to 5.0% and less than or equal to 11.0% at the screening visit.
  • Participants with both T2DM and Hepatic Impairment have clinical laboratory test results within normal range or deemed clinically insignificant by the investigator. Abnormalities of serum glucose, serum lipids, urinary glucose, and urinary protein consistent with T2DM are acceptable.

Exclusion criteria

Exclusion Criteria:

  • Have significant history of, or current, cardiovascular, respiratory, hepatic (applies to Group 1 only), renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs.
  • Have a history or presence of pancreatitis, elevation in serum amylase or lipase (greater than 1.5-fold ) or GI disorder or any GI disease, which impacts gastric emptying.
  • Have any abnormality in the 12-lead at screening.
  • Have severe atopy or have a history of multiple or severe drug allergies or severe post treatment reactions.
  • Have a history of, or current psychiatric disorders.
  • Women who are pregnant, intend to become pregnant or are breastfeeding a child are not eligible to participate.
  • Have taken any glucose-lowering medications other than metformin, sulfonylureas, and insulin, in the past 6 weeks or 5 half-lives (whichever is longer) prior to planned dosing.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    1 mg LY3502970 (Control: Normal Hepatic Function)

    Participants with normal hepatic function received a single 1 milligram (mg) dose of LY3502970 administered orally on Day 1.

    Drug: LY3502970

  • Experimental
    1 mg LY3502970 (Mild Hepatic Impairment)

    Participants with mild hepatic impairment received a single 1 mg dose of LY3502970 administered orally on Day 1.

    Drug: LY3502970

  • Experimental
    1 mg LY3502970 (Moderate Hepatic Impairment)

    Participants with moderate hepatic impairment received a single 1 mg dose of LY3502970 administered orally on Day 1.

    Drug: LY3502970

  • Experimental
    1 mg LY3502970 (Severe Hepatic Impairment)

    Participants with severe hepatic impairment received a single 1 mg dose of LY3502970 administered orally on Day 1.

    Drug: LY3502970

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of LY3502970

    PK: AUC (0-∞) of LY3502970.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point (AUC0-tlast) of LY3502970

    PK: AUC0-tlast of LY3502970.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1

  3. PK: Maximum Observed Concentration (Cmax) of LY3502970

    PK: Cmax of LY3502970.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1

07

Results

Posted May 27, 2026

Participant flow

Participant flow — Overall Study
Milestone1 mg LY3502970 (Control: Normal Hepatic Function)1 mg LY3502970 (Mild Hepatic Impairment)1 mg LY3502970 (Moderate Hepatic Impairment)1 mg LY3502970 (Severe Hepatic Impairment)
Started11666
Received at least one dose of ly350297011666
Completed11666
Not completed0000

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of LY3502970

PK: AUC (0-∞) of LY3502970.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1
Reported as:
Geometric mean · nanogram *hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of LY3502970
nanogram *hour per milliliter (ng*h/mL)1 mg LY3502970 (Control: Normal Hepatic Function)1 mg LY3502970 (Mild Hepatic Impairment)1 mg LY3502970 (Moderate Hepatic Impairment)1 mg LY3502970 (Severe Hepatic Impairment)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of LY3502970130 ± 26.8132 ± 60.2209 ± 32.6611 ± 84.6
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point (AUC0-tlast) of LY3502970

PK: AUC0-tlast of LY3502970.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1
Reported as:
Geometric mean · ng*h/mL
PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point (AUC0-tlast) of LY3502970
ng*h/mL1 mg LY3502970 (Control: Normal Hepatic Function)1 mg LY3502970 (Mild Hepatic Impairment)1 mg LY3502970 (Moderate Hepatic Impairment)1 mg LY3502970 (Severe Hepatic Impairment)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point (AUC0-tlast) of LY3502970109 ± 29.1112 ± 64.0169 ± 32.7385 ± 54.7
PrimaryPK: Maximum Observed Concentration (Cmax) of LY3502970

PK: Cmax of LY3502970.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose on Day 1
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of LY3502970
nanograms per milliliter (ng/mL)1 mg LY3502970 (Control: Normal Hepatic Function)1 mg LY3502970 (Mild Hepatic Impairment)1 mg LY3502970 (Moderate Hepatic Impairment)1 mg LY3502970 (Severe Hepatic Impairment)
PK: Maximum Observed Concentration (Cmax) of LY35029705.10 ± 21.05.47 ± 57.56.12 ± 43.65.95 ± 36.1

Adverse events

Collected over Baseline up to end of follow-up (up to 14 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1 mg LY3502970 (Control: Normal Hepatic Function)0/11 (0%)0/11 (0%)2/11 (18.2%)
1 mg LY3502970 (Mild Hepatic Impairment)0/6 (0%)0/6 (0%)1/6 (16.7%)
1 mg LY3502970 (Moderate Hepatic Impairment)0/6 (0%)0/6 (0%)1/6 (16.7%)
1 mg LY3502970 (Severe Hepatic Impairment)0/6 (0%)0/6 (0%)0/6 (0%)
Most frequent other events
Most frequent other events
Event1 mg LY3502970 (Control: Normal Hepatic Function)1 mg LY3502970 (Mild Hepatic Impairment)1 mg LY3502970 (Moderate Hepatic Impairment)1 mg LY3502970 (Severe Hepatic Impairment)
Abdominal discomfortGastrointestinal disorders1/110/61/60/6
PruritusSkin and subcutaneous tissue disorders0/111/60/60/6
DiarrhoeaGastrointestinal disorders1/110/60/60/6
HeadacheNervous system disorders1/110/60/60/6

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)1 mg LY3502970 (Control: Normal Hepatic Function)1 mg LY3502970 (Mild Hepatic Impairment)1 mg LY3502970 (Moderate Hepatic Impairment)1 mg LY3502970 (Severe Hepatic Impairment)Total
Mean54.1 ± 11.258.8 ± 14.664.3 ± 5.547.5 ± 6.855.8 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)1 mg LY3502970 (Control: Normal Hepatic Function)1 mg LY3502970 (Mild Hepatic Impairment)1 mg LY3502970 (Moderate Hepatic Impairment)1 mg LY3502970 (Severe Hepatic Impairment)Total
Female431412
Male735217
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1 mg LY3502970 (Control: Normal Hepatic Function)1 mg LY3502970 (Mild Hepatic Impairment)1 mg LY3502970 (Moderate Hepatic Impairment)1 mg LY3502970 (Severe Hepatic Impairment)Total
Hispanic or Latino734418
Not Hispanic or Latino432211
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1 mg LY3502970 (Control: Normal Hepatic Function)1 mg LY3502970 (Mild Hepatic Impairment)1 mg LY3502970 (Moderate Hepatic Impairment)1 mg LY3502970 (Severe Hepatic Impairment)Total
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American20002
White856625
More than one race00000
Unknown or Not Reported10001
Region of Enrollment
Region of Enrollment(Participants)1 mg LY3502970 (Control: Normal Hepatic Function)1 mg LY3502970 (Mild Hepatic Impairment)1 mg LY3502970 (Moderate Hepatic Impairment)1 mg LY3502970 (Severe Hepatic Impairment)Total
United States1166629
08

Study locations

4 sites
  • Clinical Pharmacology of Miami
    Miami, Florida 33014, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Nov 2024, 17 months.

Results were first posted in May 2026, 1 year 6 months after primary completion.

Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 17 months is above that.

Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2023
First posted
May 31, 2023
StartActual
Jun 13, 2023
Primary completionActual
Nov 18, 2024
CompletionActual
Nov 18, 2024
Results first posted
May 27, 2026
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05882032
Responsible party
Sponsor
First posted
May 31, 2023
Start date
Jun 13, 2023
Primary completion
Nov 18, 2024
Completion
Nov 18, 2024
Results posted
May 27, 2026
Last update
May 27, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion